May 29, 2013
Besides treating cancer, peptide receptor radionuclide therapy with radiolabeled somatostatin analogs may offer a novel approach to treating inflammation in the atherosclerotic plaques of patients with CVD, results from a new study suggest.
“Our results should act as a stimulus for further exploration of radionuclide-based interventions in atherosclerosis. Ultimately such therapies might be used to lower the degree of inflammation in atherosclerosis, which has the potential to reduce the occurrence of heart attacks,” study researcher Imke Schatka, a resident in the department of nuclear medicine at Hannover Medical School in Germany, said in a press release. Schatka presented the data at the International Conference on Nuclear Cardiology and Cardiac CT.